GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Total Assets

Sino Biopharmaceutical (HKSE:01177) Total Assets : HK$71,809 Mil (As of Jun. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Total Assets?

Sino Biopharmaceutical's Total Assets for the quarter that ended in Jun. 2024 was HK$71,809 Mil.

Warning Sign:

If a company builds assets at 23.9% a year, faster than its revenue growth rate of 3.7% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Sino Biopharmaceutical's average Total Assets Growth Rate was 5.40% per year. During the past 3 years, the average Total Assets Growth Rate was 14.10% per year. During the past 5 years, the average Total Assets Growth Rate was 23.90% per year. During the past 10 years, the average Total Assets Growth Rate was 25.50% per year.

During the past 13 years, Sino Biopharmaceutical's highest 3-Year average Total Assets Growth Rate was 52.70%. The lowest was 5.80%. And the median was 29.40%.

Total Assets is connected with ROA %. Sino Biopharmaceutical's annualized ROA % for the quarter that ended in Jun. 2024 was 9.19%. Total Assets is also linked to Revenue through Asset Turnover. Sino Biopharmaceutical's Asset Turnover for the quarter that ended in Jun. 2024 was 0.24.


Sino Biopharmaceutical Total Assets Historical Data

The historical data trend for Sino Biopharmaceutical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Total Assets Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41,743.95 55,964.80 74,133.34 71,541.53 69,569.61

Sino Biopharmaceutical Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76,116.04 71,541.53 71,796.73 69,569.61 71,809.48

Sino Biopharmaceutical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Sino Biopharmaceutical's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=41749.489+27820.119
=69,570

Sino Biopharmaceutical's Total Assets for the quarter that ended in Jun. 2024 is calculated as

Total Assets=Total Equity (Q: Jun. 2024 )+Total Liabilities (Q: Jun. 2024 )
=45345.822+26463.655
=71,809

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (HKSE:01177) Total Assets Explanation

Total Assets is connected with ROA %.

Sino Biopharmaceutical's annualized ROA % for the quarter that ended in Jun. 2024 is

ROA %=Net Income (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=6496.212/( (69569.608+71809.478)/ 2 )
=6496.212/70689.543
=9.19 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Sino Biopharmaceutical's Asset Turnover for the quarter that ended in Jun. 2024 is

Asset Turnover
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=17089.485/( (69569.608+71809.478)/ 2 )
=17089.485/70689.543
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Sino Biopharmaceutical Total Assets Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Executives
Tse Eric S Y 2101 Beneficial owner
Tse Ping 2101 Beneficial owner
Cheng Cheung Ling 2101 Beneficial owner
True Merit Global Limited 2101 Beneficial owner
Tse Theresa Y Y 2101 Beneficial owner
Thousand Eagles Limited 2101 Beneficial owner
France Investment (china 1) Group Limited 2101 Beneficial owner
Remarkable Industries Limited 2101 Beneficial owner
Validated Profits Limited 2101 Beneficial owner

Sino Biopharmaceutical Headlines

No Headlines